London, UK – AstraZeneca, a prominent UK pharmaceutical company, is under fire as it admits to the rare but deadly blood-clotting condition that could result from its COVID-19 vaccine. This acknowledgment opens the door to potential lawsuits against the company, with lawyers representing numerous claimants estimating the cases to be worth as much as $25 million each. They argue that the vaccine is a defective product.
In February, AstraZeneca officially recognized that its vaccine could cause thrombosis with thrombocytopenia syndrome (TTS) in very rare cases. This condition can lead to dangerous blood clots and low blood platelet counts, sometimes resulting in severe harm or death.
Although the potential side effect was mentioned since the vaccine’s release, the recent legal document marks the first time AstraZeneca has confirmed it in court. As a result, 51 cases have been filed in London’s High Court, estimated to be worth approximately $125 million.
Taxpayers will bear the financial burden of any payouts resulting from the claims due to a prior agreement between AstraZeneca and the UK government. Among the claimants is Jamie Scott, an IT engineer and father of two, who suffered a permanent brain injury from a blood clot after receiving the vaccine in April 2021. Scott’s wife, Kate, hopes that the company’s admission will accelerate their case, leading to an apology and fair compensation.
While AstraZeneca expresses sympathy for those allegedly harmed by the vaccine, the company defends it as a net positive. It emphasizes that complications are exceedingly rare, citing evidence from clinical trials and real-world data. The AstraZeneca COVID-19 vaccine was first authorized for emergency use in December 2020. Since then, 81 people in the UK, where around 50 million doses were administered, have died from blood clots potentially linked to the jab, according to the Medicines and Healthcare products Regulatory Agency.
Although the odds of developing TTS from the vaccine are calculated to be about 1 in 50,000, the University of Oxford, the institution in partnership with AstraZeneca for the vaccine’s development, credits it with saving as many as 6 million lives worldwide during the pandemic.
As the lawsuits against AstraZeneca continue, the outcome will determine the company’s liability and influence public perception regarding the vaccine’s safety.